PharmaShots | Incisive News in 3 Shots

Subscribe Now

Faron

$Faron Highlighted Positive P-I/II Study (BEXMAB) Results of Bexmarilimab for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes$

Faron Highlighted Positive P-I/II Study (BEXMAB) Results of Bexmarilimab for Relapsed/Refractory Acute Myeloid Leukemia and Myelod...

July 19, 2023

Faron Reports 12-Month Survival Results of Bexmarilimab in P-I/II (MATINS) Study for the Treatment of Solid Tumor

Faron Reports 12-Month Survival Results of Bexmarilimab in P-I/II (MATINS) Study for the Treatment of Solid Tumor

June 16, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us